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ABSTRACT:  Methlenetetrahydrofolate (CH2-H4folate) is required for the conversion of homocys-
teine to methionine and of dUMP to dTMP in support of DNA synthesis, and also serves as a major
source of one carbon unit for purine biosynthesis. This review presents biochemical studies of a
human polymorphism in methylenetetrahydrofolate reductase, which catalyzes the reaction shown
below. The mutation decreases the flux of CH2-H4folate into CH3-H4folate, and is associated with
both beneficial and deleterious effects that can be traced to the molecular effect of the substitution
of alanine 222 by valine. © 2002 The Japan Chemical Journal Forum and John Wiley & Sons, Inc.
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Introduction
One of the more remarkable chemical syntheses carried out by
biological organisms is the de novo biosynthesis of methyl
groups. Du Vigneaud and Bennett are credited with the initial
observations that rats could synthesize methionine from ho-
mocysteine in the absence of a source of preformed methyl
groups, and this synthesis was later shown to require the pres-
ence of folate and cobalamin in the diet. Extensive studies in
the laboratories of Stokstad, Huennekens, Buchanan, and
Weissbach identified the enzymes responsible for de novo syn-
thesis of methyl groups in mammals as methylenetetra-
hydrofolate reductase and methionine synthase and elucidated
the roles of folic acid, riboflavin, and cobalamin as cofactors in
these reactions. An excellent history of these early studies is
provided by Blakley.1
A major source of the methylene group of methylene-
tetrahydrofolate is the β-carbon of serine, which is transferred
to tetrahydrofolate by the action of serine hydroxymethyl-
transferase, as shown in Equation 1. Alternate sources of the
methylene group include formate, which is converted to 10-
formyltetrahydrofolate, and thence to methenyl- and finally
methylenetetrahydrofolate by the action of formyltetra-
hydrofolate synthetase, methenyltetrahydrofolate cyclohydro-
lase, and methylenetetrahydrofolate dehydrogenase.2
Methylenetetrahydrofolate is reduced to methyltetrahydro-
folate by methylenetetrahydrofolate reductase, as shown in
Equation 2. The enzyme contains noncovalently bound flavin
adenine dinucleotide as a cofactor; the flavin accepts reducing
equivalents from NAD(P)H and transfers them to methylene-
tetrahydrofolate.
Methionine synthase catalyzes the transfer of the nascent
methyl group from methyltetrahydrofolate to homocysteine,
Po l y m o r p h i s m  o f  M e t h y l e n e t e t r a h y d r o f o l a t e  R e d u c t a s e
© 2002 The Japan Chemical Journal Forum and John Wiley & Sons, Inc. 5
forming methionine and tetrahydrofolate, as shown in Equa-
tion 3. Some prokaryotes have two alternative methionine syn-
thase enzymes, a cobalamin-independent enzyme and a
cobalamin-dependent enzyme. In Escherichia coli, the former
is the product of the metE gene, and is often referred to as
MetE, while the latter is the product of the metH gene. Mam-
mals, including humans, have only the cobalamin-dependent
methionine synthase (homologous to MetH), while plants,
Archaea, and yeast have only MetE homologues.
CH2-H4folate not only provides one-carbon units for me-
thionine biosynthesis and remethylation of homocysteine, but
also for the conversion of dUMP to dTMP in the reaction
catalyzed by thymidylate synthase, and for purine biosynthesis
following conversion of CH2-H4folate to 10-formyl-H4folate.
Regulation of flux through these competing reactions is ac-
complished in part by allosteric inhibition of MTHFR by
adenosylmethionine (AdoMet), a major cellular methyl donor
that is derived from methionine and reflects the availability of
methionine in the cell. In this instance, AdoMet serves as a
regulatory molecule but does not transfer a methyl group to
MTHFR.
The pathway from methylenetetrahydrofolate to me-
thionine in humans has become a topic of considerable medi-
cal interest with the discovery that elevated levels of
homocysteine in human plasma, hyperhomocysteinemia, are
associated with significant risks for the development of car-
diovascular disease and Alzheimer’s disease in adults and for
neural tube defects in the developing fetus.3–5 Mutations in
methylenetetrahydrofolate reductase that lead to loss of en-
zyme function are associated with severe hyperhomo-
cysteinemia and aggressive development of cardiovascular
disease.6 In addition, a common C677T polymorphism in
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the human MTHFR gene that leads to substitution of Ala
222 by Val,7,8 is associated with mild hyperhomocysteinemia
in humans, and may therefore be a risk factor. Mutations lead-
ing to loss of function in methionine synthase also lead to se-
vere hyperhomocysteinemia.
This review is focused on our studies of methylene-
tetrahydrofolate reductase. The purification and characteriza-
tion of the porcine enzyme, and particularly the elucidation of
peptide sequence, made possible the cloning and sequencing
of the gene specifying the human enzyme and the discovery of
the common C677T polymorphism. The potential medical
importance of this polymorphism, and the emerging recogni-
tion of the role of dietary folate supplementation in lowering
mild hyperhomocysteinemia in humans, in turn led to studies
of methylenetetrahydrofolate reductase from E. coli, and con-
struction of a homologue of the C677T mutation in the E. coli
enzyme. These studies led to the determination of the X-ray
structure of E. coli methylenetetrahydrofolate reductase. And
more recently, we have returned to the mammalian enzymes,
developing a system for successful overexpression of the hu-
man enzyme and characterizing the biochemical phenotype of
the C677T polymorphism in the human enzyme. Our research
has been driven by the conviction that understanding cellular
biochemistry at the molecular level is a necessary prerequisite
for treatment of human disease. Our biochemical studies have
been carried out in parallel with complementary studies by
structural biologists, geneticists, and physicians, and this in-




Methylenetetrahydrofolate reductase was initially purified sev-
eral 100-fold from pig liver and shown to be a flavoprotein.9
The FAD cofactor was shown to be alternately reduced by
NADPH and reoxidized by methylenetetrahydrofolate. The pig
liver enzyme was purified to homogeneity in my laboratory
with a 32,000-fold enrichment in specific activity as compared
to a pig liver homogenate.10
My interest in this enzyme was initially engendered by the
observation that tetrahydrofolate, like dihydroflavin, is a redox
cofactor. I wondered if the reduction of methylene- to
methyltetrahydrofolate might exploit the redox properties of
the substrate, as shown in Equation 4. The facile catalysis of
NADPH-linked reduction of menadione, and of quininoid 6,7-
dimethyldihydropterins (1) by methylenetetrahydrofolate re-
ductase supported this hypothesis. However, when the flavin
cofactor is substituted by 8-demthyl-8-hydroxy-5-deaza-5-
carbaflavin adenine dinucleotide (5-deazaFAD), the enzyme
catalyzes NADPH-linked reduction of methylenetetrahy-
drofolate at >50% the rate of native FAD-containing enzyme.11
5-DeazaFAD readily accepts and donates hydride ions but
is unable to accept or donate single electrons because the semi-
quinone oxidation state is destabilized.12,13 Because reduction
of 5-deazaFAD leads to incorporation of hydride into a nonex-
changeable position on the deazaflavin, the regiospecificity of
hydride transfer from deazaflavin hydroquinone to the sub-
strates can be determined.14 Tritium from (5S)-[5-3H]-5-
(3)
(4)
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deazaFAD is incorporated quantitatively into both NADP+ and
methylenetetrahydrofolate, consistent with hydride transfer
mechanisms. Furthermore, these studies indicated that each
substrate in turn reacts at the si face of the flavin cofactor, con-
sistent with the Bi-Bi ping-pong kinetics, in which release of
the first product precedes binding of the second substrate, which
has been previously observed with this enzyme.
Mammalian MTHFRs are polypeptides of 70–77 kDa,
and the porcine enzyme has been shown to be a homodimer.15
Each subunit contains two distinct regions, an N-terminal re-
gion that shares homology with the smaller prokaryotic
MTHFRs and is thus presumed to be responsible for catalysis
of the overall reaction, and a C-terminal region that is unique
to the eukaryotic MTHFRs. The C-terminal region has been
shown to bind AdoMet, and is thought to be involved in allos-
teric regulation of MTHFR activity in response to AdoMet
levels in the cell.16
Despite the fact that 4 kg of pig liver only yielded about 1
mg of homogenous protein, James Sumner laboriously obtained
peptide sequences for about 40% of methylenetetrahydrofolate
reductase from pig liver. These peptide sequences allowed the
cloning of the human MTHFR cDNA.7,8
Methylenetetrahydrofolate Reductase from
E. coli
Characterization of mammalian MTHFRs has been a challenge
because of the very low level of enzyme activity in mammalian
tissues. Early attempts at expressing recombinant human
MTHFR in bacterial cells produced very low levels of activity,
which were not suitable for isolation of enzyme in amounts
appropriate for biochemical characterization.8 We therefore
developed procedures for overexpression and purification of
histidine-tagged MTHFR from E. coli.17 The bacterial enzyme
could be expressed at high levels, yielding about 55 mg of pu-
rified enzyme per liter of cell culture and could be easily puri-
fied using a nickel affinity column. The purified enzyme is a
homotetramer of 33 kDa subunits. Sequence comparisons indi-
cate that the E. coli enzyme differs from its mammalian coun-
terpart in that it lacks a C-terminal regulatory domain. The
sequence of the N-terminal catalytic domain of the human
enzyme is 30% identical to the E. coli sequence.18
While the mammalian enzyme is a homodimer, the
prokaryotic enzyme is a homotetramer.17 However, the gross
structure of the two enzymes may be similar. Scanning trans-
mission electron microscopy revealed that the porcine enzyme
consists of four globular domains arranged in a planar rosette;
these four domains are presumably the two catalytic domains
and the two regulatory domains of the homodimer. The X-ray
structure of the enzyme from E. coli,18 to be described in detail
below, revealed that the four identical subunits are also arranged
in a planar rosette.
The other respect in which the E. coli enzyme differs sig-
nificantly from the human enzyme is in its specificity for NADH
rather than NADPH.17 Mammalian MTHFR enzymes cata-
lyze essentially irreversible reductions of CH2-H4folate due to
the large standard free energy of the reaction (–6.39 kcal, cal-
culated from reference 19) and the high ratio of NADPH to
NADP+ in mammalian cell cytoplasm. Because the NADH/
NAD+ ratio in cell cytoplasm is very low,20 the NADH-linked
reaction is freely reversible.21 Methylenetetrahydrofolate reduc-
tase from higher plants is also NADH-dependent, and although
the plant enzymes contain a regulatory domain, they are not
inhibited by AdoMet.21
An extensive kinetic characterization of the E. coli enzyme
has been performed using stopped-flow spectrophotometry.22
Comparison of the rates of flavin reduction by NADH and of
flavin reoxidation by CH2-H4folate measured in the stopped-
flow spectrophotometer with kcat for steady-state turnover in
the NADH-CH2-H4folate oxidoreductase reaction indicates
that the enzyme is kinetically competent to catalyze this reac-
tion by a ping-pong Bi-Bi mechanism (Fig. 1). Reoxidation of
the reduced flavin by CH2-H4folate is largely rate-limiting in
the overall reaction.
The X-ray structure of MTHFR from E. coli was deter-
mined in collaboration with Brian Guenther and Martha
Ludwig.18 This structure revealed that MTHFR is a β8α8 bar-
Fig. 1. Kinetic mechanisms for methylenetetrahydrofolate reductase.
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rel that binds FAD in the center of the barrel. The MTHFR
structure provided a satisfying rationale for the ping-pong ki-
netics observed with MTHFR. The re-face of the FAD is com-
pletely shielded by the barrel, and only the si face, the face
known to react with substrates, is exposed. Thus, the two sub-
strates, NADPH and CH2-H4folate, must occupy partially over-
lapping sites on the si face of the flavin, so that binding of one
substrate precludes binding of the other. Such kinetic mecha-
nisms are characterized by excess substrate inhibition, which
results when binding of NADPH to the reduced enzyme, or of
methylenetetrahydrofolate to the oxidized enzyme, results in
formation of dead-end complexes.23
The X-ray structure of methylenetetrahydrofolate reductase
provides insights into the role of the protein in facilitating reduc-
tion of CH2-H4folate. A structure with the substrate bound has
not yet been published, but 10-formyl-H4folate can be positioned
on the si face of the flavin with the carbon of its formyl group
positioned for hydride transfer to N5 of the flavin, and with two
invariant active site residues, Gln 183 and Asp120, positioned to
form hydrogen bonding interactions with the pterin ring.24
The proposed mechanism for reduction of CH2-H4folate
is shown in Scheme 1, and it is based on model studies of the
condensation of formaldehyde with H4folate, which suggested
the formation of a 5-iminium cation as an intermediate in the
reaction.25 Reduction is initiated by a general acid-catalyzed
protonation of N10 of CH2-H4folate, and opening of the
imidazolidine ring to form the 5-iminium cation. This ex-
tremely reactive species has never been directly observed in any
enzymatic or nonenzymatic reaction, although the N5-
carbinolamine formed by attack of water on this species has
been detected during the reaction of formaldehyde with
H4folate,
25 and at the active site of thymidylate synthase, an
enzyme that catalyzes transfer of the methylene group of CH2-
H4folate to dUMP.
26 Once formed, the 5-iminium cation can
by reduced by hydride transfer from N5 of the reduced flavin
to form CH3-H4folate.
The X-ray structure of E. coli methylenetetrahydrofolate
reductase suggests that Glu 28 is positioned appropriately to
serve as the general acid catalyst for protonation of N10, either
by direct proton transfer or via water. The Glu28Gln mutant
of E. coli methylenetetrahydrofolate reductase is unable to cata-
lyze the reduction of CH2-H4folate.
24 Titration of the mutant
oxidized enzyme with CH3-H4folate does not result in reduc-
tion of the flavin, although a charge transfer complex between
CH3-H4folate and oxidized flavin indicates that the mutation
does not impair binding of the folate.
Methylenetetrahydrofolate Reductase and
Human Physiology
The recent construction of a knockout mutation in the mu-
rine MTHFR gene has allowed assessment of the physiological
role of MTHFR in mice.6 Plasma total homocysteine levels in
heterozygous and homozygous knockout mice are 1.6- and 10-
fold higher than those in wild-type littermates, respectively.
Both heterozygotes and homozygotes have elevated levels of S-
adenosylhomocysteine and decreased levels of AdoMet, and
their DNA is hypomethylated. While the heterozygous mice
appear normal, the homozygous knockout mice are smaller than
their littermates and show developmental retardation. As they
mature, they show abnormal lipid deposition in the aorta, sug-
gesting an atherogenic effect of elevated plasma homocysteine
in these mice. The phenotypes of homozygous knockout mice
resemble those seen in patients with severe methylene-
tetrahydrofolate reductase deficiency; these patients suffer from
developmental delay, and some have thromboses of the arteries
and cerebral veins.27
Scheme 1. Proposed mechanism for oxidative half-reaction.
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Sequencing of the cDNAs from human patients revealed
a number of mutations that were associated with loss of func-
tion,28 as well as several polymorphisms that were common in
humans with apparently normal function.8,29 One of these poly-
morphisms, C677T in the cDNA, leads to substitution of
Ala222 by a valine residue;8 this mutation affects a residue in
the catalytic domain of MTHFR that is conserved in both
prokaryotic and eukaryotic enzymes.
The allele frequency of the C677T polymorphism is about
33–37% in European whites. About 10% of this population is
homozygous for the mutation (i.e., has the TT genotype).8 The
allele frequency of the C677T polymorphism in East Asians is
similar to that in European whites, while that frequency in sub-
Saharan Africans is 6%.30 Homozygosity for the C677T muta-
tion is associated with elevated values for serum homocyst(e)ine,
particularly in humans with low levels of blood folic acid,31
and treatment of humans with daily supplements of folic acid
leads to decreases in total homocysteine.32 An elevated level of
serum homocyst(e)ine is an established independent risk fac-
tor for cardiovascular disease,3 and is also associated with neu-
ral tube defects in the fetus.33
Our laboratory has been particularly interested in ascer-
taining the biological basis for the phenotype of the C677T
mutation, and the effect of folate supplementation on lower-
ing serum homocysteine in patients with this polymorphism,
and indeed in humans with the normal CC677 genotype. Until
very recently, efficient expression systems for human MTHFR
did not exist. Therefore, we decided to use the E. coli enzyme
as a model for the catalytic domain of the human enzyme, and
to investigate the structural and catalytic properties of the wild-
type enzyme and the enzyme containing a mutation homolo-
gous to the human Ala222Val mutation, that is, Ala177Val.
We showed that the Ala177Val mutation does not affect
the kinetic parameters for MTHFR. However, it was apparent
that the reaction velocity of the mutant enzyme decreased more
rapidly than that of the wild-type enzyme. MTHFR is a fla-
voprotein, and the noncovalently bound FAD is essential for
catalysis. Therefore, we diluted a concentrated stock of enzyme
into buffer and monitored the rate of flavin release by fluores-
cence spectroscopy. We found that the rate of activity loss after
dilution corresponded to the rate at which flavin was released
from the enzyme (C. A. Sheppard, unpublished data). Inter-
estingly, both the wild-type and mutant enzymes lost flavin on
dilution, although the mutant lost flavin at a rate 10 times
faster than the wild-type enyzme.18 In each case, the initial rate
of flavin loss varied as the square root of the enzyme concen-
tration [Fig. 2(a)]. Such kinetics would be expected if flavin
release is accompanied by dissociation of the tetramer into
dimers, and if tetramer/dimer equilibrium is established prior
to rate-limiting release of FAD, as shown in Figure 3.
These studies suggested that the hyperhomocysteinemia
observed in humans homozygous for the C677T polymorphism
might result from formation of inactive MTHFR due to flavin
dissociation from the mutant enzyme. They also suggested that
even the wild-type enzyme was susceptible to flavin loss. It was
then of great interest to determine how loss of activity on dilu-
tion could be slowed or prevented. We found that CH3-H4folate
protected both the wild-type and mutant enzymes [Fig. 2(b)]
from flavin loss, suggesting that folate supplementation might
exert its effect on serum homocysteine levels by maintaining
both mutant and wild-type MTHFR in an active holoenzyme
form.18 The X-ray structure of the bacterial enzyme determined
in Dr. Martha Ludwig’s laboratory has provided a rationale for
protection of the enzyme by folates. The positioning of the
FAD cofactor with respect to the β8α8 barrel suggested that
CH2-H4folate would bind with the pteridine ring stacked above
the flavin, and this interaction should stabilize the holoenzyme
by slowing dissociation of FAD from the enzyme on dilution.
Although binding of CH3-H4folate would be inhibitory, if we
assume that the concentration of the substrate CH2-H4folate
rises in proportion with the total folate concentration on di-
etary supplementation with folic acid, the net effect will be to
stabilize the enzyme without increasing inhibition by non-
substrate folate derivatives.
The four subunits of the tetramer are arranged in an un-
usual planar rosette (Fig. 4) that is characterized by a twofold
rather than a fourfold axis of symmetry. The interactions be-
tween subunits B and C and those between A and A′ are much
more extensive than the interactions between B and A or C
and A′. Thus, the dissociation of the tetramer into dimers rather
than monomers on dilution is rationalized by the structure.
The site of the Ala177Val mutation that is homologous to
the C677T (Ala222Val) polymorphism in humans is at the
bottom of the α8β8 barrel, far from the flavin binding site.
The side chain of Ala177 lies inside a tight loop that connects
helix 5 with strand 6 of the barrel. Although a structure of the
Val177 mutant has not yet been published, this sidechain is
more bulky than the methyl group of alanine and cannot be
accommodated inside the loop without distortions that propa-
gate helix 5. Residues on helix 5 make extensive interactions
with the ADP moiety of the FAD cofactor, suggesting that these
interactions are weakened in the Val177 mutant and flavin dis-
sociation is enhanced. Thus, the X-ray structure provides a
molecular rationale for the phenotype associated with the
Ala177Val mutation.
Nonetheless, one may question the relevance of studies on
the bacterial enzyme to the physiology associated with the hu-
man polymorphism. Of particular concern is the fact that the
bacterial enzyme is a homotetramer of 33 kDa subunits, while
the mammalian enzymes are dimers of 77 kDa subunits con-
taining both catalytic and regulatory domains.
Dr. Kazuhiro Yamada, a postdoctoral fellow in my labora-
tory, has recently succeeded in expressing N-terminal histidine-
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Fig. 2. Reproduced, with permission, from Guenther et al.18 (a) The
Ala177Val mutation in MTHFR from E. coli is associated with an enhanced
rate of flavin dissociation. After dilution of a concentrated stock (200 µM) of
enzyme to the indicated subunit concentrations (Et), the initial rate of FAD
dissociation was ascertained for wild-type (+) and mutant (5) enzymes.
The solid lines have been calculated assuming that the rate of flavin release
varies as the square root of the enzyme concentration after dilution. Inset:
The change in fluorescence versus time is shown for wild-type (lower trace)
and mutant (upper trace) enzymes diluted to 500 nm concentration. (b) Pro-
tection of wild-type and mutant enzymes against flavin loss after dilution in
the presence of CH3-H4folate. The initial rate of flavin loss from 500 nm
wild-type (2) and mutant (5) enzymes is plotted against the concentration
of (6S)CH3-H4folate monoglutamate present after dilution. The initial rates
have been corrected for fluorescence increases associated with the slow oxida-
tion of CH3-H4folate catalyzed by the enzyme under aerobic conditions.
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tagged human methylenetetrahydrofolate reductase at high lev-
els using a baculovirus expression system in insect Sf9 cells. He
has constructed the C677T mutant, and has purified both the
wild-type and mutant enzymes to homogeneity using nickel
affinity chromatography. Comparison of the properties of the
wild-type and mutant enzymes has revealed that our studies on
the Ala177Val mutant of the bacterial enzyme have provided a
very good working model for the effect of the C677T polymor-
phism on the human enzyme.34 In particular, the mutation leads
to enhanced rates of flavin dissociation, accompanied by disso-
ciation of the dimer into monomers and loss of activity, and
CH3-H4folate protects the enzyme against loss of activity.
Our studies suggest that the negative effects of the human
C677T polymorphism, particularly the mild elevation in serum
homocysteine, should be preventable with dietary folate supple-
mentation. They also suggest a rationale for the observation that
folate supplementation is effective in lowering serum homocys-
teine in most humans, regardless of their MTHFR genotype,
because the normal enzyme is also susceptible to loss of flavin,
and this loss can be retarded by folate supplementation.
Why should a potentially deleterious mutation be so com-
mon in humans? Its persistence in the population suggests ben-
eficial properties at least under some conditions. Recent studies
have shown that the 677TT genotype is linked to a lower risk
of colon cancer and certain childhood leukemias.35,36 The ra-
tionale for the protective effect of the mutation is thought to
be that the mutation decreases the flux of CH2-H4folate into
CH3-H4folate, sparing CH2-H4folate for the conversion of
dUMP into dTMP under folate limiting conditions. While
this sparing effect may lead to decreased risks for certain can-
cers, it probably also is protective to the fetus, and thus might
confer benefits that justify the retention of the polymorphism
at high levels in many human populations.
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